---
schema_version: "secwatch.filing_event.v1"
accession: "0001279569-24-000603"
form_type: "8-K"
ticker: null
cik: "0001633932"
company_name: "ESSA Pharma Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:52:12.929230+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ESSA Pharma Q2 net loss $9.0M; Phase 1 masofaniten combo shows 81% PSA90 in mCRPC

## Summary
- Net loss $9.0M (Q2 2024) vs $7.1M (Q2 2023); R&D expense $6.2M; cash $135.9M, sufficient beyond 2025.
- Phase 1 masofaniten+enzalutamide: 81% PSA90, 69% within 90 days, 63% PSA<0.2 ng/mL; median PSA progression 16.6 months.
- Phase 2 enrollment completion expected Q1 2025; preliminary data mid-2025; ~25 sites active, 15 European sites by Q3 2024.
- Additional arms enrolling: masofaniten+abiraterone/prednisone and +apalutamide; Phase 1b monotherapy results H2 2024.

## SEC filing metadata
- accession: 0001279569-24-000603
- form_type: 8-K
- cik: 0001633932
- company_name: ESSA Pharma Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1633932/000127956924000603/0001279569-24-000603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1633932/000127956924000603/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001279569-24-000603
- JSON: https://secwatch.observer/filing/0001279569-24-000603.json
- Plain text: https://secwatch.observer/filing/0001279569-24-000603.txt

## Key facts
- Earnings Releases
  ESSA Pharma Inc. reported fiscal second quarter ended March 31, 2024 results: net income $9.0 million.
  - Period: fiscal second quarter ended March 31, 2024
  - Net income: $9.0 million
  - Result: reported results
  source text: Net Loss. ESSA recorded a net loss of $9.0 million for the second quarter ended March 31, 2024 compared to $7.1 million for the second quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1633932/000127956924000603/0001279569-24-000603-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.